Study to investigate the safety, tolerability and pharmacokinetics of single doses ofAZD2551
Study identifier:D1570C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Double Blind, Randomised, Placebo-controlled, Phase I Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single, Ascending, Oral Doses of AZD2551 in Healthy Male Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD2551, Placebo
Sex
Male
Actual Enrollment
90
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Feb 2009
Primary Completion Date: -
Study Completion Date: 01 May 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD2551 Single dose of oral solution. |
| Placebo Comparator: 2 | Drug: Placebo Single dose of oral solution |
Contacts
Investigators
Principal Investigator
William Fahy
AstraZeneca Clinical Pharmacology Unit, E Floor, Queens Medical Centre, Nottingham NG7 2UH
